OpGen

OpGen Long-term Debt

The Long-Term Debt of OpGen (OPGN) as of Oct 23, 2026 is 4.85 M USD. In the previous year, Long-Term Debt was 7.18 M USD — a change of -32.41% (lower).

Long-term Debt

4.85 MUSD

YoY

-32.41%

Last updated:

Long-Term Debt of OpGen is 2022 4.85 M USD. Long-Term Debt of OpGen was 2021 7.18 M USD. It decreases by -32.41% lower compared to the previous year.

The OpGen Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2015
1.32 M USD
Jan 1, 2016
146,540.00 USD
Jan 1, 2017
130,150.00 USD
Jan 1, 2018
660,340.00 USD
Jan 1, 2019
329,456.00 USD
Jan 1, 2020
19.38 M USD
Jan 1, 2021
7.18 M USD
Jan 1, 2022
4.85 M USD
The OpGen Long-term Debt history
YEARLong-term DebtYoY
4.85 MUSD-32.41%
7.18 MUSD-62.97%
19.38 MUSD+5,782.10%
329,456.00USD-50.11%
660,340.00USD+407.37%
130,150.00USD-11.18%
146,540.00USD-88.92%
1.32 MUSD+886.86%
134,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Long-Term Debt of OpGen is 4.85 M USD in 2022.

Long-Term Debt of OpGen changed from 7.18 M USD to 4.85 M USD, representing a -32.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt OpGen since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen